Ascendis Pharma A (ASND) EBIT Margin (2014 - 2026)
Ascendis Pharma A's EBIT Margin came in at 64.98% for the quarter ended Jun 30, 2026, up 98.48 percentage points from -33.50% a year earlier and up 54.92 percentage points from the prior quarter.
Ascendis Pharma A (ASND) EBIT Margin (2014 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Ascendis Pharma A reported EBIT Margin of 25.36%, up 76.89 percentage points year-over-year; for the year ended Dec 31, 2025, it was -18.92%, up 49.78 percentage points from the prior year.
- EBIT Margin has increased in each of the last four years, with a five-year change of +4736.15 percentage points (years ended Dec 2020 to Dec 2025).
- Going back by year, EBIT Margin was -68.70% in the year ended Dec 31, 2024 (+102.10 pp), -170.79% in the year ended Dec 31, 2023 (+927.06 pp), -1097.85% in the year ended Dec 31, 2022 (+4710.74 pp) and -5808.59% in the year ended Dec 31, 2021 (-1053.52 pp).
- The figure for the quarter ended Jun 30, 2026 represents the highest quarterly EBIT Margin in data going back to the quarter ended Mar 31, 2014.
- Year-over-year, EBIT Margin has increased for five consecutive quarters, with an average year-over-year change of +99.69 percentage points over the last eight quarters.
- The fastest year-over-year change in EBIT Margin over five years came in the quarter ended Mar 31, 2022 (a gain of 14834.06 percentage points), and the weakest in the quarter ended Sep 30, 2021 (a drop of 5849.99 percentage points).
- Business Quant data shows ASND's EBIT Margin at 10.06% (quarter ended Mar 31, 2026), 4.00% (quarter ended Dec 31, 2025) and 5.15% (quarter ended Sep 30, 2025) in the three quarters before the quarter ended Jun 30, 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | Ascendis Pharma A | 14.26 Bn | 10.50 Bn | 362.22 Mn | 64.98% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.98% |
| Mar 31, 2026 | 10.06% |
| Dec 31, 2025 | 4.00% |
| Sep 30, 2025 | 5.15% |
| Jun 30, 2025 | -33.50% |
| Mar 31, 2025 | -103.23% |
| Dec 31, 2024 | 0.22% |
| Sep 30, 2024 | -167.28% |
| Jun 30, 2024 | -370.18% |
| Mar 31, 2024 | -51.25% |
| Dec 31, 2023 | -12.09% |
| Sep 30, 2023 | -279.82% |
| Jun 30, 2023 | -297.17% |
| Mar 31, 2023 | -427.77% |
| Dec 31, 2022 | -643.75% |
| Sep 30, 2022 | -945.09% |
| Jun 30, 2022 | -2,303.46% |
| Mar 31, 2022 | -1,875.06% |
| Dec 31, 2021 | -130.71% |
| Sep 30, 2021 | -8,709.07% |
Ascendis Pharma A EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();